Skip to main content
FATE logo

Fate Therapeutics, Inc.

FATENASDAQHealthcareBiotechnology

$1.93Today:- (-)1Y +25.00%

As of Oct 15, 2026 close

Market cap
$231.76M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.95$3.23
Volume (live)
-
Avg. volume (3M)
1.43M

Fate Therapeutics (FATE) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Fate Therapeutics used $106.08M of cash in operating activities and spent $5.95M on capital expenditures. That left free cash flow of −$112.04M.

Fate Therapeutics Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Fate Therapeutics, Inc. (FATE) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-136.32-186.26-160.93-281.72-212.15-173.39-98.15-66.60-42.95
Depreciation & Amortization12.9018.9618.2813.765.853.092.191.200.97
Deferred Income Tax0.000.000.000.000.000.00-0.48-0.340.01
Stock Based Compensation24.9241.5043.4678.7354.3630.7517.416.293.61
Change in Working Capital-3.74-1.9619.18-34.712.10-12.773.641.742.08
Change in Accounts Receivable2.62-1.1136.65-29.80-3.16-5.520.50-0.500.00
Change in Inventory0.000.000.000.000.000.00-4.28-4.250.00
Change in Accounts Payable-9.03-1.66-28.9414.250.00-1.554.284.252.51
Change in Other Working Capital2.660.82-40.86-24.015.26-5.703.142.24-0.43
Other Operating Activities-3.844.89-40.86-24.01-13.03108.31-7.7919.04-0.61
Net Cash from Operating Activities-106.08-122.87-132.26-248.21-162.87-39.23-83.18-38.65-36.91
Investing Activities
Capital Expenditures-5.95-0.73-6.15-35.57-50.70-4.93-7.40-2.30-1.73
Acquisitions0.360.000.000.000.000.00150.060.000.00
Purchases of Investments-195.14-317.75-358.81-404.80-968.16-156.14-248.86-55.66-39.97
Sales/Maturities of Investments311.90330.70477.63607.11694.84121.2098.8057.5031.50
Other Investing Activities0.000.000.000.000.000.00-150.061.84-8.47
Net Cash from Investing Activities111.1712.22112.67166.75-324.02-161.08-157.45-0.46-10.20
Financing Activities
Debt Repayment0.000.000.000.000.000.00-15.000.004.15
Common Stock Issued0.0094.820.099.21411.74282.35162.41134.5843.21
Other Financing Activities5.495.070.000.0041.390.492.526.200.16
Net Cash from Financing Activities5.4999.890.099.21453.13282.84149.93140.7847.44
Summary
Effect of Forex Changes on Cash0.004.950.050.000.00-15.000.000.000.00
Net Change in Cash10.57-5.81-19.51-72.25-33.7682.53-90.70101.670.34
Cash at Beginning of Period46.2841.8776.56148.81182.5799.81190.7489.0788.73
Cash at End of Period56.8636.0657.0576.56148.81167.35100.04190.7489.07
Free Cash Flow-112.04-123.60-138.42-283.77-213.57-44.16-90.57-40.95-38.63

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Fate Therapeutics Cash Flow

What is Fate Therapeutics's free cash flow?

Fate Therapeutics had negative free cash flow of $112.04M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$106.08M minus $5.95M of capital expenditures.

How much does Fate Therapeutics spend on capital expenditures?

Fate Therapeutics spent $5.95M on capital expenditures in fiscal 2025, compared with $730.00K a year earlier.

Does Fate Therapeutics pay dividends or buy back shares?

Fate Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition